The Evaluation of Clinical, Demographic, Radiological Characteristics and Treatment Responce of Multiple Sclerosis Patients in Thrace Region
Öz
Aim: In this study we retrospectively evaluated clinical, demographic, epidemiologic features and treatment modalities of the multiple sclerosis (MS) patients who applied to Trakya University Medical Faculty Neurology Department 2005–2013 years, from our archives.
Material and Method: Among 210 MS patients, 126 (% 60) patients were female and 84 (% 40) patients were male in our study.
Female/male ratio was 3/2. The mean age of all patients was 40.7±10.6, the mean age of males was 42±10.8 and the mean age
of females was 39.9±10.5. The average age of disease onset of patients was 31.1±10.0 (32.5±10.4 among males, 30.2±9.6 among
females). While the average disease duration of patients were 9.6±6.7 years (9.4±6.6 years for males, 9.7±6.7 years for females).
Results: When we classified the multiple sclerosis patients according to multiple sclerosis subtypes, we found that 145 patients
(% 69) had Relapsing Remitting MS (RRMS), 11 patients (% 5.2) had Primer Progressive MS (PPMS), 5 patients (% 2.4) had
Seconder Progressive MS (SPMS), 30 patients (% 14.3) Relapsing Progressive MS (RPMS) and 19 patients (% 9) had Clinical Isolated Syndrome (CIS). In PPMS group, the mean age of patients was 52.7±9.2, the average age of disease onset was 39.8±11.7, and the disease duration was 12.9±6.1 years. We found that in patients of PPMS group the mean age and average age of disease onset were higher and the duration of disease was longer, additionally the male gender was higher in PPMS group compared with RRMS group.
Anahtar Kelimeler
Kaynakça
- 1. R K. Multipl skleroz: İmmunopatogenetik özellikler. Ankara: ADA Basın Yay Ltd Şti 2013:191–2.
- 2. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. The Lancet Neurol 2010, 9:520–32.
- 3. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoim Rev 2010, 9: A387–94.
- 4. Oksenberg JR, Barcellos LF. The complex genetic aetiology of multiple sclerosis. J Neurovirol 2000, 6 Suppl 2: S10–4.
- 5. H M. Multiple skleroz hastalığı ve yaşam kalitesi. Sağlıkta Birikim 2006, 12:77–82.
- 6. M E. Multiple Skleroz İle Yaşamı Nasıl Kolaylaştırırız?, İstanbul Tıp Fak Hast Okulu Yay 2005:3.
- 7. Compston A, Coles A. Multiple sclerosis. Lancet 2008, 372:1502–17.
- 8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol 1983, 33:1444–52.
- 9. Turk Boru U, Alp R, Sur H, Gul L. Prevalence of multiple sclerosis door-to-door survey in Maltepe, Istanbul, Turkey. Neuroepidemiol 2006, 27:17–21.
- 10. Çelik Y BO, Kiyat A. Prevalence of multiple sclerosis in the metropolitan area of Edirne City. Balkan Med J 2011, 28:193–96.
- 11. Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Part one. Acta Neurol Scandinavica 1975, 51:110–36.
- 12. 2008 WHO. World Health Organization. Atlas: Multiple Sclerosis Resources in the World 2008. Geneva, Switzerland 2013.
- 13. Bulut S KH, Demir CF. Yukarı Fırat Bölgesinde multipl skleroz tanısı ile izlenen hastaların klinik ve demografik özellikleri. Fırat Tıp Derg 2011, 16:84–90.
- 14. Terzi M OM. Multipl sklerozda klinik ve demografik özellikler 21:149–55.
- 15. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, Turan F, Ozmenoglu M, Togrul E, Demirkiran M. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurol 1998, 51:765–72.
- 16. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, Milanov I. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006, 13:700–22.
- 17. Houzen H, Niino M, Kikuchi S, Fukazawa T, Nogoshi S, Matsumoto H, Tashiro K. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003, 211:49–53.
- 18. Compston A. The 150th anniversary of the first depiction of the lesions of multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry 1988, 51:1249–52.
- 19. Pittock SJ, Lucchinetti CF. The pathology of MS. new insights and potential clinical applications. Neurol 2007, 13:45–56.
- 20. Clanet M. Jean-Martin Charcot 1825 to 1893. Int MS J/MS Forum 2008, 15:59–61.
- 21. Solaro C, Allemani C, Messmer Uccelli M, Canevari E, Dagnino N, Pizio R, Regesta G, Tanganelli P, Battaglia MA, Mancardi GL. The prevalence of multiple sclerosis in the northwest Italian province of Genoa. J Neurol 2005, 252:436–40.
- 22. Modrego Pardo PJ, Latorre MA, Lopez A, Errea JM. Prevalence of multiple sclerosis in the province of Teruel, Spain. J Neurol 1997, 244:182–5.
- 23. Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Pirastru MI, Murgia B, Mannu L, Sanna G, Rosati G. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol Scandinavica 2001, 103:20–6.
- 24. Rodriguez M, Siva A, Ward J, Stolp-Smith K, O’Brien P, Kurland L. Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurol 1994, 44:28–33.
- 25. Bufill E, Blesa R, Galan I, Dean G. Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain. J Neurol, Neurosurg Psychiatry 1995, 58:577–81.
- 26. Negreiros AA, Sousa-Munoz RL, Oliveira BE, Nobrega PV, Monteiro LL. Clinical and epidemiological profile of patients diagnosed with multiple sclerosis in Joao Pessoa, Paraiba, Brazil. Arq Neuro-psiquiatr 2015, 73:741–5.
Trakya Bölgesindeki Multipl Sklerozis Tanısı ile Takipli Hastaların Klinik, Demografik, Radyolojik Özellikleri ve Tedavi Yanıtlarının Değerlendirilmesi
Öz
Amaç: Çalışmada 2005–2013 yılları arasında Trakya Üniversitesi Tıp Fakültesi Nöroloji Anabilim Dalı’nda takip edilen Multipl Sklerozis (MS) tanısı almış hastaların klinik, demografik, epidemiyolojik verilerini ve kullandıkları tedavileri retrospektif olarak arşivlerden incelendi.
Materyal ve Metot: Çalışmaya dahil edilen 210 hastanın 126’sı (%60) kadın, 84’ü (%40) erkekti, kadın/erkek oranı ise 3/2 olarak
saptandı. Tüm hastaların yaş ortalaması 40,7±10,6 iken, erkeklerin yaş ortalaması 42±10,8, kadınların yaş ortalaması ise 39,9±10,5’ti. Hastalık başlangıç yaşı ortalaması 31,1±10 saptandı. Erkeklerde başlangıç yaşı ortalaması 32,5±10,4 iken kadınlarda 30,2± 9,6 olduğu görüldü. Vakaların ortalama hastalık süresi 9,6±6,7 yıl iken, erkeklerde ortalama hastalık süresi 9,4±6,6 yıl, kadınlarda ortalama hastalık süresi 9,7±6,7 yıldı.
Bulgular: Multipl skleroz tanısıyla takip edilen hastalar MS klinik alt tiplerine göre sınıflandırıldığında Relapsing Remitting MS tanılı
145 (%69), Primer Progresif MS (PPMS) tanılı 11 (%5,2), Sekonder Progresif MS tanılı 5 (%2,4), Relapsing Progresif MS tanılı 30 (%14,3) ve Klinik izole Sendrom tanılı 19 (%9) hasta olduğu görüldü. Klinik alt tiplerden PPMS’te hastaların yaş ortalaması 52,7 ±9,2 iken, hastalık başlangıç yaşı ortalaması 39,8±11,7 ve hastalık süresi 12,9±6,1 yıl olduğu tespit edilmiştir. PPMS grubunda kadın/erkek oranı 0,22 iken RRMS’de ise kadın/erkek oranı 1,73 olarak saptandı. PPMS grubundaki hastalar RRMS grubundaki hastalar ile yaş ortalaması, başlangıç yaşı ve hastalık süresi açısından karşılaştırıldığında; PPMS grubunun yaş ortalaması ve başlangıç yaşının RRMS grubuna göre daha geç ve hastalık süresinin daha uzun olduğu tespit edildi.
Sonuç: Çalışmada elde edilen veriler literatür ile birlikte değerlendirildiğinde, literatürdeki verilerle benzer sonuçların olduğu
görülmüştür.
Anahtar Kelimeler
Kaynakça
- 1. R K. Multipl skleroz: İmmunopatogenetik özellikler. Ankara: ADA Basın Yay Ltd Şti 2013:191–2.
- 2. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. The Lancet Neurol 2010, 9:520–32.
- 3. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoim Rev 2010, 9: A387–94.
- 4. Oksenberg JR, Barcellos LF. The complex genetic aetiology of multiple sclerosis. J Neurovirol 2000, 6 Suppl 2: S10–4.
- 5. H M. Multiple skleroz hastalığı ve yaşam kalitesi. Sağlıkta Birikim 2006, 12:77–82.
- 6. M E. Multiple Skleroz İle Yaşamı Nasıl Kolaylaştırırız?, İstanbul Tıp Fak Hast Okulu Yay 2005:3.
- 7. Compston A, Coles A. Multiple sclerosis. Lancet 2008, 372:1502–17.
- 8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol 1983, 33:1444–52.
- 9. Turk Boru U, Alp R, Sur H, Gul L. Prevalence of multiple sclerosis door-to-door survey in Maltepe, Istanbul, Turkey. Neuroepidemiol 2006, 27:17–21.
- 10. Çelik Y BO, Kiyat A. Prevalence of multiple sclerosis in the metropolitan area of Edirne City. Balkan Med J 2011, 28:193–96.
- 11. Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Part one. Acta Neurol Scandinavica 1975, 51:110–36.
- 12. 2008 WHO. World Health Organization. Atlas: Multiple Sclerosis Resources in the World 2008. Geneva, Switzerland 2013.
- 13. Bulut S KH, Demir CF. Yukarı Fırat Bölgesinde multipl skleroz tanısı ile izlenen hastaların klinik ve demografik özellikleri. Fırat Tıp Derg 2011, 16:84–90.
- 14. Terzi M OM. Multipl sklerozda klinik ve demografik özellikler 21:149–55.
- 15. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, Turan F, Ozmenoglu M, Togrul E, Demirkiran M. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurol 1998, 51:765–72.
- 16. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, Milanov I. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006, 13:700–22.
- 17. Houzen H, Niino M, Kikuchi S, Fukazawa T, Nogoshi S, Matsumoto H, Tashiro K. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003, 211:49–53.
- 18. Compston A. The 150th anniversary of the first depiction of the lesions of multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry 1988, 51:1249–52.
- 19. Pittock SJ, Lucchinetti CF. The pathology of MS. new insights and potential clinical applications. Neurol 2007, 13:45–56.
- 20. Clanet M. Jean-Martin Charcot 1825 to 1893. Int MS J/MS Forum 2008, 15:59–61.
- 21. Solaro C, Allemani C, Messmer Uccelli M, Canevari E, Dagnino N, Pizio R, Regesta G, Tanganelli P, Battaglia MA, Mancardi GL. The prevalence of multiple sclerosis in the northwest Italian province of Genoa. J Neurol 2005, 252:436–40.
- 22. Modrego Pardo PJ, Latorre MA, Lopez A, Errea JM. Prevalence of multiple sclerosis in the province of Teruel, Spain. J Neurol 1997, 244:182–5.
- 23. Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Pirastru MI, Murgia B, Mannu L, Sanna G, Rosati G. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol Scandinavica 2001, 103:20–6.
- 24. Rodriguez M, Siva A, Ward J, Stolp-Smith K, O’Brien P, Kurland L. Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurol 1994, 44:28–33.
- 25. Bufill E, Blesa R, Galan I, Dean G. Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain. J Neurol, Neurosurg Psychiatry 1995, 58:577–81.
- 26. Negreiros AA, Sousa-Munoz RL, Oliveira BE, Nobrega PV, Monteiro LL. Clinical and epidemiological profile of patients diagnosed with multiple sclerosis in Joao Pessoa, Paraiba, Brazil. Arq Neuro-psiquiatr 2015, 73:741–5.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Konular | Klinik Tıp Bilimleri |
| Bölüm | Araştırma Makalesi |
| Yazarlar | |
| Yayımlanma Tarihi | 1 Aralık 2017 |
| Yayımlandığı Sayı | Yıl 2017 Yıl: 2017 Sayı: 3 |